SGLT2 inhibitors in metabolic dysfunction-associated steatotic liver disease (MASLD/NAFLD): Mechanisms, clinical benefits, and outcomes
Advances in Clinical and Experimental Medicine · 2026
DOI: 10.17219/acem/209813 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advances in Clinical and Experimental Medicine, 2026. Verfasst von Jan Paleček und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, 1st Faculty of Medicine Charles University, Military University Hospital Prague, Czech Republic. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Sodium-Glucose Transporter 2 Inhibitors, Metabolic Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).
Abstract (Originalsprache)
Metabolic dysfunction-associated steatohepatitis (MASH) represents a progressive form of metabolic dysfunction-associated steatotic liver disease (MASLD) and contributes significantly to morbidity and mortality in developed countries. Current clinical practice primarily relies on dietary and lifestyle modifications, while specialized obesity management is used less frequently. However, the long-term efficacy of these approaches remains unsatisfactory. Among pharmacological options, gliflozins have emerged as a promising class of agents with potential benefits in reducing histological activity and improving the prognosis of MASLD/MASH. The beneficial effects of gliflozins in diabetes, cardiology, and nephrology have already been demonstrated, and their use is becoming increasingly common across various clinical indications. However, their role in the treatment of MASLD/MASH has not yet been fully clarified. Preliminary studies suggest that gliflozins may positively influence disease progression in these conditions. This article provides a comprehensive overview of MASLD/MASH and reviews current evidence regarding the therapeutic effects of gliflozins on these liver diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, 1st Faculty of Medicine Charles University, Military University Hospital Prague, Czech Republic.
- Department of Military Internal Medicine and Military Hygiene, Military Faculty of Medicine, University of Defense, Hradec Kralove, Czech Republic.
- Department of Pathology, Military University Hospital Prague, Czech Republic.
- 3rd Department of Internal Medicine-Metabolism and Gerontology, University Hospital Hradec Kralove, Czech Republic.
Zitieren
APA
Paleček, J., Hříbek, P., Ždarská, D. J., Nováková, M., Skořepa, P., & Urbánek, P. (2026). SGLT2 inhibitors in metabolic dysfunction-associated steatotic liver disease (MASLD/NAFLD): Mechanisms, clinical benefits, and outcomes. Advances in Clinical and Experimental Medicine. https://doi.org/10.17219/acem/209813
Vancouver
Paleček J, Hříbek P, Ždarská DJ, Nováková M, Skořepa P, Urbánek P. SGLT2 inhibitors in metabolic dysfunction-associated steatotic liver disease (MASLD/NAFLD): Mechanisms, clinical benefits, and outcomes. Advances in Clinical and Experimental Medicine. 2026. doi:10.17219/acem/209813
BibTeX
@article{Paleek2026,
author = {Paleček, Jan and Hříbek, Petr and Ždarská, Denisa Janíčková and Nováková, Marie and Skořepa, Pavel and Urbánek, Petr},
title = {SGLT2 inhibitors in metabolic dysfunction-associated steatotic liver disease (MASLD/NAFLD): Mechanisms, clinical benefits, and outcomes},
journal = {Advances in Clinical and Experimental Medicine},
year = {2026},
doi = {10.17219/acem/209813}
}
EUVIMED